|
|||
|
Multiple Sclerosis Info
|
Thursday, February 28
Tysabri warning to doctors
by
multiplesclerosis
on Thu 28 Feb 2008 09:05 AM CST
Dear Healthcare Professional,
Biogen ldec and Elan are writing to inform you of new safety information regarding TYSABRI" (natalizumab). The full Prescribing Information has been revised to add to the more »
FDA: Biogen Idec's Tysabri may harm liver
by
multiplesclerosis
on Thu 28 Feb 2008 08:15 AM CST
A letter posted to the Food and Drug Administration's Web site says that patients taking Tysabri, which is manufactured at a facility in Research Triangle Park, have developed signs of liver injury as soon as six days after taking their first dose. more »
Saturday, February 23
Tysabri - Frequently Asked Questions 3 of 3
by
multiplesclerosis
on Sat 23 Feb 2008 01:00 AM CST
Q. Where can I call to get more information about Tysabri?
The Tysabri Care Program is a registry that supports the safe and effective use of Tysabri. Its goals are to:
· To inform people about the risks and benefits of Tysabri prior to treatment more »
Friday, February 22
Tysabri - Frequently Asked Questions 2 of 3
by
multiplesclerosis
on Fri 22 Feb 2008 12:00 AM CST
Q. Will my insurance cover the cost of Tysabri?
A. According to Biogen Idec Canada, most private insurers are now reimbursing the cost of Tysabri. Generally insurance companies require prior authorization before they will more »
Thursday, February 21
Tysabri - Frequently Asked Questions 1 of 3
by
multiplesclerosis
on Thu 21 Feb 2008 07:32 PM CST
Q. What is Tysabri (pronounced Tie-SAB-bree) and how does it work?
A. Tysabri (whose scientific name is natalizumab, pronounced: nat-tal-IZ-zue-mab) is a laboratory-produced monoclonal antibody. It was formerly called Antegren. It had been approved for more »
Monday, February 18
Delayed natalizumab (tysabri) allergy seen in patient with multiple sclerosis
by
multiplesclerosis
on Mon 18 Feb 2008 12:00 AM CST
Although most hypersensitive reactions to natalizumab (Tysabri) occur within hours of the first dose, such responses may be delayed, according to more »
Sunday, February 10
Natalizumab Has Benefits on Disability
by
multiplesclerosis
on Sun 10 Feb 2008 10:29 AM CST
natalizumab results in significant improvements in scores on health-related quality of life (QoL) questionnaires in patients more »
Tuesday, February 5
A Controlled Trial of Tysabri (Natalizumab) for Relapsing Multiple Sclerosis
by
multiplesclerosis
on Tue 05 Feb 2008 08:15 AM CST
The glycoprotein integrin is expressed on the surface of these cells and plays a critical part in their adhesion to the vascular endothelium and migration into the parenchyma. Tysabri (Natalizumab) is an integrin antagonist that reduced the development of brain lesions in more »
Monday, December 31
NICE Recommends TYSABRI® for Use in Highly Active Relapsing Remitting Multiple Sclerosis
by
multiplesclerosis
on Mon 31 Dec 2007 09:51 AM CST
NICE Recommends TYSABRI® for Use in Highly Active Relapsing Remitting Multiple Sclerosis Final Guidance Issued on First MS Treatment Recommended by NICE MAIDENHEAD, ... more » Saturday, September 30
Tysabri Improves Cognitive Function in MS
by
multiplesclerosis
on Sat 30 Sep 2006 10:29 AM CST
New Data on Natalizumab Demonstrate Significant Improvement in Cognitive Function in Patients With Multiple Sclerosis ZUG, SWITZERLAND and DUBLIN, IRELAND – September ... more » |
||
